vs
Legacy Housing Corp（LEGH）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Legacy Housing Corp的1.4倍（$35.5M vs $25.5M），Legacy Housing Corp净利率更高（32.2% vs -304.2%，领先336.4%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -30.6%），Legacy Housing Corp自由现金流更多（$15.7M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -9.1%）
Legacy Housing Corp是美国知名的经济型预制住宅、微型住宅及配套居住单元制造商，主要面向北美中低收入消费群体，提供可定制住房解决方案、配套建材及相关售后服务，服务个人及社区开发类客户。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
LEGH vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.5M | $35.5M |
| 净利润 | $8.2M | $-108.1M |
| 毛利率 | 26.4% | 59.8% |
| 营业利润率 | 40.4% | -304.8% |
| 净利率 | 32.2% | -304.2% |
| 营收同比 | -30.6% | 681.7% |
| 净利润同比 | -43.5% | 39.6% |
| 每股收益（稀释后） | $0.38 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $25.5M | $35.5M | ||
| Q3 25 | $28.8M | $5.2M | ||
| Q2 25 | $38.4M | $19.2M | ||
| Q1 25 | $24.3M | $14.7M | ||
| Q4 24 | $36.7M | $4.5M | ||
| Q3 24 | $30.2M | $26.1M | ||
| Q2 24 | $31.7M | $14.4M | ||
| Q1 24 | $30.8M | $13.8M |
| Q4 25 | $8.2M | $-108.1M | ||
| Q3 25 | $8.6M | $-162.3M | ||
| Q2 25 | $14.7M | $-171.9M | ||
| Q1 25 | $10.3M | $-202.5M | ||
| Q4 24 | $14.5M | $-178.9M | ||
| Q3 24 | $15.8M | $-95.8M | ||
| Q2 24 | $16.2M | $-97.5M | ||
| Q1 24 | $15.1M | $-91.4M |
| Q4 25 | 26.4% | 59.8% | ||
| Q3 25 | 20.2% | -183.8% | ||
| Q2 25 | 32.4% | -4.9% | ||
| Q1 25 | 29.2% | -48.0% | ||
| Q4 24 | 27.3% | -181.4% | ||
| Q3 24 | 29.2% | 53.7% | ||
| Q2 24 | 31.9% | 36.2% | ||
| Q1 24 | 33.6% | 19.1% |
| Q4 25 | 40.4% | -304.8% | ||
| Q3 25 | 33.7% | -3327.6% | ||
| Q2 25 | 43.8% | -916.8% | ||
| Q1 25 | 47.7% | -1297.9% | ||
| Q4 24 | 42.3% | -4042.4% | ||
| Q3 24 | 50.8% | -377.1% | ||
| Q2 24 | 50.6% | -697.4% | ||
| Q1 24 | 54.3% | -698.4% |
| Q4 25 | 32.2% | -304.2% | ||
| Q3 25 | 30.0% | -3135.3% | ||
| Q2 25 | 38.3% | -894.2% | ||
| Q1 25 | 42.3% | -1373.3% | ||
| Q4 24 | 39.5% | -3935.5% | ||
| Q3 24 | 52.4% | -367.5% | ||
| Q2 24 | 51.1% | -676.6% | ||
| Q1 24 | 49.1% | -662.4% |
| Q4 25 | $0.38 | $-0.17 | ||
| Q3 25 | $0.35 | $-0.36 | ||
| Q2 25 | $0.60 | $-0.41 | ||
| Q1 25 | $0.41 | $-0.50 | ||
| Q4 24 | $0.59 | $-0.56 | ||
| Q3 24 | $0.64 | $-0.34 | ||
| Q2 24 | $0.65 | $-0.40 | ||
| Q1 24 | $0.60 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $528.6M | $1.1B |
| 总资产 | $580.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $8.5M | $743.3M | ||
| Q3 25 | $13.6M | $659.8M | ||
| Q2 25 | $2.6M | $525.1M | ||
| Q1 25 | $3.4M | $500.5M | ||
| Q4 24 | $1.1M | $594.4M | ||
| Q3 24 | $570.0K | $427.6M | ||
| Q2 24 | $60.0K | $474.3M | ||
| Q1 24 | $621.0K | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $528.6M | $1.1B | ||
| Q3 25 | $521.6M | $1.0B | ||
| Q2 25 | $512.8M | $919.1M | ||
| Q1 25 | $503.7M | $933.9M | ||
| Q4 24 | $494.0M | $1.0B | ||
| Q3 24 | $479.3M | $524.6M | ||
| Q2 24 | $463.2M | $584.4M | ||
| Q1 24 | $450.4M | $401.2M |
| Q4 25 | $580.3M | $1.5B | ||
| Q3 25 | $557.9M | $1.4B | ||
| Q2 25 | $552.0M | $1.3B | ||
| Q1 25 | $544.6M | $1.3B | ||
| Q4 24 | $534.2M | $1.4B | ||
| Q3 24 | $521.4M | $726.5M | ||
| Q2 24 | $514.9M | $775.9M | ||
| Q1 24 | $510.0M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.0M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $15.7M | $-47.3M |
| 自由现金流率自由现金流/营收 | 61.6% | -133.1% |
| 资本支出强度资本支出/营收 | 13.1% | 3.5% |
| 现金转化率经营现金流/净利润 | 2.32× | — |
| 过去12个月自由现金流最近4个季度 | $28.2M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $19.0M | $-46.1M | ||
| Q3 25 | $7.2M | $-117.4M | ||
| Q2 25 | $6.1M | $-76.4M | ||
| Q1 25 | $4.9M | $-132.0M | ||
| Q4 24 | $7.9M | $-115.4M | ||
| Q3 24 | $13.8M | $-59.2M | ||
| Q2 24 | $3.5M | $-82.2M | ||
| Q1 24 | $10.8M | $-102.3M |
| Q4 25 | $15.7M | $-47.3M | ||
| Q3 25 | $5.1M | $-117.6M | ||
| Q2 25 | $3.7M | $-79.6M | ||
| Q1 25 | $3.6M | $-133.8M | ||
| Q4 24 | $6.0M | $-116.7M | ||
| Q3 24 | $9.1M | $-63.8M | ||
| Q2 24 | $1.7M | $-83.4M | ||
| Q1 24 | $9.9M | $-109.0M |
| Q4 25 | 61.6% | -133.1% | ||
| Q3 25 | 17.8% | -2272.5% | ||
| Q2 25 | 9.6% | -413.9% | ||
| Q1 25 | 15.0% | -907.4% | ||
| Q4 24 | 16.4% | -2567.7% | ||
| Q3 24 | 30.2% | -244.6% | ||
| Q2 24 | 5.4% | -578.5% | ||
| Q1 24 | 32.2% | -789.9% |
| Q4 25 | 13.1% | 3.5% | ||
| Q3 25 | 7.1% | 4.7% | ||
| Q2 25 | 6.2% | 16.4% | ||
| Q1 25 | 5.2% | 12.4% | ||
| Q4 24 | 5.1% | 28.6% | ||
| Q3 24 | 15.6% | 17.5% | ||
| Q2 24 | 5.5% | 8.2% | ||
| Q1 24 | 2.8% | 48.2% |
| Q4 25 | 2.32× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.71× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LEGH
| Commercial Sales | $8.6M | 34% |
| Retail Store Sales | $6.0M | 24% |
| Inventory Finance Sales | $5.0M | 20% |
| Direct Sales | $4.4M | 17% |
| Other | $1.5M | 6% |
RXRX
暂无分部数据
